Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Does not yet support clinical interventions targeting CVB-enhancing antibodies in T1D; leaves open a potential pathogenic mechanism for future research.
Hober et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: